Efficacy of dulaglutide 1.5 mg combined with insulin in older, poorly controlled insulin-treated patients with long-standing type 2 diabetes: a post-hoc analysis

被引：0
|
作者：
Lando, L. Fernandez [1 ]
Patel, H. [1 ]
Yu, M. [2 ]
Pantalone, K. M. [3 ]
机构：
[1] Eli Lilly & Co, Indianapolis, IN USA
[2] Eli Lilly & Co, Toronto, ON, Canada
[3] Cleveland Clin, Dept Endocrinol, Cleveland, OH 44106 USA
来源：
DIABETOLOGIA | 2017年 / 60卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
827
引用
收藏
页码：S382 / S383
页数：2
相关论文
共 50 条
  • [41] Efficacy of Dulaglutide in Chinese Patients with Type 2 Diabetes and Different Glycemic Patterns: a Post-hoc Analysis of the Phase 3 AWARD-CHN2 Trial
    Qifu Li
    Qiqi Zhang
    Rui Wang
    Tianpei Hong
    Diabetes Therapy, 2022, 13 : 161 - 173
  • [42] Efficacy of Dulaglutide in Chinese Patients with Type 2 Diabetes and Different Glycemic Patterns: a Post-hoc Analysis of the Phase 3 AWARD-CHN2 Trial
    Li, Qifu
    Zhang, Qiqi
    Wang, Rui
    Hong, Tianpei
    DIABETES THERAPY, 2022, 13 (01) : 161 - 173
  • [43] Efficacy and Safety of Once-Weekly Dulaglutide in Type 2 Diabetes Patients Using Insulin: Exploratory Subgroup Analysis by Insulin Regimen
    Yukiko Onishi
    Hitoshi Ishii
    Tomonori Oura
    Masakazu Takeuchi
    Diabetes Therapy, 2020, 11 : 735 - 745
  • [44] CGM-based measurements for once-weekly insulin icodec vs once-daily insulin glargine U100 in insulin-treated patients with type 2 diabetes: a post hoc analysis
    Bajaj, H. S.
    Bang, R. Beck
    Gowda, A.
    Liu, L.
    Senior, P.
    Bergenstal, R.
    DIABETOLOGIA, 2021, 64 (SUPPL 1) : 266 - 266
  • [45] Efficacy and Safety of Once-Weekly Dulaglutide in Type 2 Diabetes Patients Using Insulin: Exploratory Subgroup Analysis by Insulin Regimen
    Onishi, Yukiko
    Ishii, Hitoshi
    Oura, Tomonori
    Takeuchi, Masakazu
    DIABETES THERAPY, 2020, 11 (03) : 735 - 745
  • [46] "Surpass(ing)" an era of basal-bolus insulin therapy: tirzepatide vs insulin lispro tid added-on to poorly controlled basal insulin-treated type 2 diabetes
    Frias, J. P.
    Rosenstock, J.
    Rodbard, H. W.
    Tofe, S.
    Sears, E.
    Huh, R.
    Lando, L. Fernandez
    Patel, H.
    DIABETOLOGIA, 2023, 66 (SUPPL 1) : S5 - S6
  • [47] A Randomized Study to Evaluate the Efficacy of Insulclock Pen Device in Insulin-Treated Patients with Uncontrolled Type 2 Diabetes
    Ramos, Clementina
    Galindo, Rodolfo J.
    Alam, Muhammad M.
    Cardona, Saumeth
    Albury, Bonnie S.
    Oladejo, Omolade
    Pasquel, Francisco J.
    Vellanki, Priyathama
    Fayfman, Maya
    Migdal, Alexandra
    Davis, Georgia
    Haw, Jeehea Sonya
    Umpierrez, Guillermo E.
    DIABETES, 2020, 69
  • [48] Efficacy and Safety of Intermittent Fasting in People With Insulin-Treated Type 2 Diabetes (INTERFAST-2)-A Randomized Controlled Trial
    Obermayer, Anna
    Tripolt, Norbert J.
    Pferschy, Peter N.
    Kojzar, Harald
    Aziz, Faisal
    Mueller, Alexander
    Schauer, Markus
    Oulhaj, Abderrahim
    Aberer, Felix
    Sourij, Caren
    Habisch, Hansjoerg
    Madl, Tobias
    Pieber, Thomas
    Obermayer-Pietsch, Barbara
    Stadlbauer, Vanessa
    Sourij, Harald
    DIABETES CARE, 2023, 46 (02) : 463 - 468
  • [49] Predictors of hypoglycaemia in insulin-treated type 2 diabetes patients in primary care: A retrospective database analysis
    Kostev, Karel
    Dippel, Franz-Werner
    Rathmann, Wolfgang
    PRIMARY CARE DIABETES, 2014, 8 (02) : 127 - 131
  • [50] GLP-1 agonists and insulin in obese insulin-treated patients with type 2 diabetes: combined treatment or substitution? Weight and metabolic benefits
    Bertoin, F.
    Paoli, A.
    Ancelle, D.
    Decoudier, B.
    Francois, M.
    Lukas-Croisier, C.
    Bertin, E.
    Crouzet, M.
    Moysset, P.
    Hecart, A. -C.
    Malgrange, D.
    Delemer, B.
    DIABETOLOGIA, 2012, 55 : S298 - S299
12345